NOTE registry

The purpose of the NOTE registry is to evaluate the efficacy and safety of nonvitamin K oral antagonists (NOACs) for thromboembolic prevention in adult patients with CHD. The principal investigator is Professor Barbara Mulder, M.D., PhD at the University of Amsterdam. The primary objective of the registry is to evaluate the two year incidence of thromboembolic and bleeding events in consecutive CHD patients using NOACs for thromboembolic prevention. The secondary objectives of the registry are to evaluate adherence to NOAC therapy and the quality of life when using NOACs, and to identify CHD-specific risk factors for thromboembolism. The registry is currently enrolling subjects. For further information please contact Hayang Yang ( or Barbara Mulder (